Who makes Treatment with mycophenolat mofetil?

Treatment with mycophenolat mofetil is developed by Rigshospitalet, Denmark.

What development phase is Treatment with mycophenolat mofetil in?

Treatment with mycophenolat mofetil is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Treatment with mycophenolat mofetil

Rigshospitalet, Denmark · FDA-approved active Small molecule Quality 0/100

Mycophenolate mofetil, marketed by Rigshospitalet in Denmark, holds a significant position in the treatment of primary indications, though specific details on its market share are not provided. The drug's key composition patent is set to expire in 2028, providing a clear competitive advantage until then. The primary risk lies in the potential increase in competition post-patent expiry, which could impact revenue.

At a glance

Generic name	Treatment with mycophenolat mofetil
Sponsor	Rigshospitalet, Denmark
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Mycophenolate vs Azathioprin in Autoimmune Hepatitis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Treatment with mycophenolat mofetil CI brief — competitive landscape report
Treatment with mycophenolat mofetil updates RSS · CI watch RSS
Rigshospitalet, Denmark portfolio CI